WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that a U.S. Food and Drug Administration’s (FDA) Circulatory System Devices Panel meeting is scheduled to review AtriCure’s Premarket Approval Application (PMA) for its Synergy Ablation System on October 26, 2011. AtriCure submitted the final module of its PMA in December 2010 for an atrial fibrillation indication during open-heart concomitant procedures.
